Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Beating Heart Mitral Valve Repair With the HARPOON™ System

A legfontosabb adatok

Ki végzi
Edwards Lifesciences
Hol
Ann Arbor, Atlanta, Baltimore, Murray, Nashville, Portland, Rochester és San Francisco (Egyesült Államok)Mind a 9 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
25 fő vett részt
Kezdés
2020. dec. 16.
Várható befejezés
2027. dec. 20.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • HARPOON™ Beating Heart Mitral Valve Repair System
A regiszteradat frissítve
2026. augusztus 19.

Ki vehet részt

Életkor
21 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 40 feltétel megnézéseKevesebb

Ki vehet részt

  • Each subject is required to meet all of the following inclusion criteria:
  • Patient is >/= 21 years old
  • Presence of severe degenerative mitral regurgitation with mid-segment posterior leaflet prolapse (without commissural involvement) by echocardiographic study
  • Mitral leaflet coaptation surface sufficient to reduce mitral regurgitation without undue leaflet tension, based on the judgment of the Echocardiographic Core Lab
  • Patient competent to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation

Ki nem vehet részt

  • Have undergone cardiac or peripheral vascular procedures within 30 days prior to the trial procedure
  • Requirement for concomitant cardiac surgery
  • Previous structural heart intervention (e.g. any heart valve replacement or repair procedures). Previous percutaneous coronary intervention (PCI) is allowed
  • Previous coronary artery bypass grafting (CABG)
  • Stroke within 30 days prior to index procedure
  • ST segment elevation myocardial infarction (STEMI) requiring intervention within 30 days prior to index procedure
  • Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments (as assessed by Case Review Committee)
  • Planned treatment with any other investigational device or procedure through 1-year follow-up, or who are currently participating in an investigational drug or device trial
  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
  • Planned cardiac or peripheral vascular procedures within 30 days after the trial procedure
  • Severe pulmonary hypertension (pulmonary artery systolic pressure > 60mmHg)
  • Severe aortic stenosis or insufficiency
  • Any history of endocarditis
  • Contraindication to cardiac surgery, including hostile chest or history of mediastinal radiation
  • Evidence of cirrhosis or hepatic synthetic failure (Child-Pugh Class B or higher, [or MELD score of ≥ 13])
  • Rheumatic heart disease including rheumatic mitral stenosis
  • Condition or conditions that, in the opinion of the Investigator, precludes participation, including willingness to comply with all follow-up procedures
  • Contraindication for transesophageal echocardiography (TEE), including esophageal spasm, esophageal stricture, esophageal laceration, esophageal perforation, esophageal diverticula (e.g. Zenker's diverticulum)
  • Left ventricular ejection fraction (LVEF) <30%, or severely impaired right ventricular dysfunction as measured by the core lab
  • Renal insufficiency CKD Stage 3b or worse (GFR < 45 ml/min/1.73 m2)
  • History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
  • Pregnant or lactating at the time of enrollment (women of childbearing age should have negative pregnancy test within 72 hours of surgery) or planning pregnancy within the next 12 months
  • Patients will be excluded if ANY of the following criteria apply:
  • Functional mitral regurgitation (FMR)
  • Evidence of anterior or bileaflet prolapse
  • Severe mitral annular calcification (MAC)
  • Moderate or greater leaflet calcification
  • Fragile or thinning apex (e.g. LV aneurysm)
  • Severe tricuspid regurgitation. (Patients with mild or moderate tricuspid regurgitation are not excluded.)
  • Hemodynamic instability or cardiogenic shock at the time of enrollment (e.g. requiring inotropic support or mechanical support devices)
  • Refuse blood products
  • Carotid stenosis ≥ to 80% at time of enrollment
  • Echocardiographic evidence of intracardiac mass (e.g. left ventricular, atrial, or appendage thrombus, myxoma, or vegetation)
  • Cannot tolerate procedural anticoagulation or post-procedure antiplatelet regimen; Intra-operative exclusion criteria
  • No longer meets eligibility criteria based on intra-operative assessment

Helyszínek itt: Egyesült Államok

  • University of Michigan Health SystemAnn Arbor, Egyesült Államok
  • Piedmont Heart InstituteAtlanta, Egyesült Államok
  • Johns HopkinsBaltimore, Egyesült Államok
  • University of Maryland Medical CenterBaltimore, Egyesült Államok
  • Intermountain Heart InstituteMurray, Egyesült Államok
  • Centennial Medical CenterNashville, Egyesült Államok
  • OHSU Knight Cardiovascular InstitutePortland, Egyesült Államok
  • Mayo ClinicRochester, Egyesült Államok
  • UCSFSan Francisco, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative mitral regurgitation (DMR).

A vizsgálat csoportja

  • HARPOON™ Beating Heart Mitral Valve Repair SystemA vizsgált kezelés

    Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Multi-center Trial to Evaluate the Safety and Effectiveness of Beating Heart Mitral Valve Repair With the HARPOON™ System (RESTORE)
A regiszteradat frissítve
2026. augusztus 19.